A recent analysis from the FIRE trial, involving 1,445 patients aged ≥75 years with myocardial infarction (MI) and multivessel disease, has revealed critical insights into the role of frailty in treatment outcomes. Patients were randomized to receive either complete revascularization or culprit-only revascularization, with a substantial focus on stratifying outcomes based on the Clinical Frailty Scale (CFS). Among the stratified cohort, 70% of patients were categorized into non-frail, pre-frail, and frail groups, allowing for a nuanced examination of treatment efficacy across varying levels of frailty.

The findings underscore the significance of frailty as an independent risk factor, with increasing frailty correlating with a 1.62-fold higher risk of adverse outcomes, including death, recurrent MI, stroke, or ischemia-driven revascularization (P = .002). Notably, the study demonstrated that complete revascularization conferred benefits across all CFS categories, with no significant interaction between the revascularization strategy and frailty status (p for interaction = 0.769). This consistency suggests that the therapeutic advantages of complete revascularization are robust, irrespective of a patient’s frailty level.

The implications of these results are profound for clinical practice and research. They advocate for a paradigm shift in the management of older MI patients, emphasizing that complete revascularization should be considered a viable option for all patients with multivessel disease, regardless of frailty status. This could influence treatment protocols and clinical guidelines, potentially accelerating the integration of comprehensive revascularization strategies in geriatric cardiology, thereby improving outcomes for a vulnerable patient population.

Source: academic.oup.com